Jacqueline S. L. Kloth

Author

Also Known As

Amin Herman, De Jager, Philip L., J S L Kloth, J. Kloth, J.S.L. Kloth, Jacqueline S L Kloth, Jacqueline S. L. Kloth, Jacqueline S.L. Kloth, Kloth, Jacqueline SL

Publications

757

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Cancer Institute The Netherlands Cancer Institute Erasmus MC Leiden University Medical Center Sint Franciscus Gasthuis

About

Jacqueline S. L. Kloth is an author at Erasmus MC Cancer Institute specializing in medicine, genetics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	149
2	Pathology	3	3	50
3	Biochemistry	1	1	26
4	Cell Biology	1	1	26
5	Immunology	1	1	26

Jacqueline S. L. Kloth

Publications

528

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours Nienke A. G. Lankheet, Jacqueline S. L. Kloth, Christa G.M. Gadellaa-van Hooijdonk, British Journal of Cancer	2014	102
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors Jacqueline S. L. Kloth, Alessia Pagani, Michiel C. Verboom, British Journal of Cancer	2015	97
Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662 Meta H.M. Diekstra, Heinz‐Josef Klümpen, Martijn P. Lolkema, Clinical Pharmacology & Therapeutics	2014	75
Disentangling the genetics of lean mass David Karasik, M. Carola Zillikens, Yi‐Hsiang Hsu, American Journal of Clinical Nutrition Body CompositionQuantitative GeneticsFitnessBody SizeGenetics	2018	47
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients Lisette Binkhorst, Jacqueline S. L. Kloth, Annelieke S. de Wit, Breast Cancer Research and Treatment	2015	37
Integrated semi‐physiological pharmacokinetic model for both sunitinib and its active metabolite <scp>SU</scp>12662 Huixin Yu, Neeltje Steeghs, Jacqueline S. L. Kloth, British Journal of Clinical Pharmacology	2014	32
Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study Jacqueline S. L. Kloth, Heinz‐Josef Klümpen, Huixin Yu, Clinical Pharmacokinetics BiochemistryMedicineClearsun StudyPredictive ValueAbcb1 Phenotyping Probes	2013	26
Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment Jacqueline S. L. Kloth, Paul Hamberg, Pauline A.J. Mendelaar, European Journal of Cancer MedicineMalignant Blood DisorderReceptor Tyrosine KinaseImmunologyCell Death	2016	26
Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib Michiel C. Verboom, Jacqueline S. L. Kloth, Jesse J. Swen, European Journal of Cancer Genetic PolymorphismsAngiogenesis-related GenesMedicineGeneticsGastrointestinal Oncology	2017	25
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence Jacqueline S. L. Kloth, Lisette Binkhorst, Annelieke S. de Wit, Clinical Pharmacokinetics	2015	22

Page 1